5-fluorouracil
(5-FU) is a fluorinated, pyrimidine analog, antineoplastic agent that is used
in the treatment of several solid organ cancers. Cardiotoxicity is uncommon but
life-threatening manifestations such as myocardial infarction may manifest
owing to 5-FU-induced coronary artery spasm. Administering smaller doses of the
drug, more frequently than not, decreases the risk of cardiotoxicity compared
to large doses or with continuous infusions. We present a case of ST-segment
elevation in a patient without known coronary artery disease who had presented following continuous 5-FU infusion. Coronary angiogram confirmed absence of coronary
artery disease and intravenous calcium channel blockers administration
was commensurate with the patient’s improvement in symptoms. We discuss the
literature on 5-FU and its association with coronary artery spasm, and also
briefly review chemotherapy-induced
cardiotoxicities to help better prepare internists and other primary
health care providers to face similar challenges, particularly of the uncommon
but potentially life-threatening manifestations.
References
[1]
American Cancer Society (2023) Learn about Cancer. American Cancer Society, Inc., 2023. https://www.cancer.org/research/cancer-facts-statistics/all- cancer-facts-figures/2023-cancer-facts-figures.html
[2]
Aksoy, M., Basu, T.K., Brient, J. and Dickerson, J.W. (1980) Thiamin Status of Patients Treated with Drug Combinations Containing 5-Fluorouracil. European Journal of Cancer, 16, 1041-1045. https://doi.org/10.1016/0014-2964(80)90251-0
Thomas, A., Bates, S., Figg Sr, D., et al. (2023) DNA Topoisomerase Targeting Drugs. In: Blast Jr., R.C., Byrd, J.C., Croce, C.M., et al., Eds., Holland-Frie Cancer Medicine. 10th Edition. Wiley Backwell, Hoboken.
[5]
Ensley, J.F., Patel, B., Kloner, R., Kish, J.A., Wynne, J. and Al-Sarraf, M. (1989) The Clinical Syndrome of 5-Fluorouracil Cardiotoxicity. Investigational New Drugs, 7, 101-109. https://doi.org/10.1007/BF00178196
[6]
Robben, N.C., Pippas, A.W. and Moore, J.O. (1993) The Syndrome of 5-Fluorouracil Cardiotoxicity. An Elusive Cardiopathy. Cancer, 71, 493-509. https://doi.org/10.1002/1097-0142(19930115)71:2<493::AID-CNCR2820710235>3.0.CO;2-C
[7]
Meyer, C.C., Calis, K.A., Burke, L.B., Walawander, C.A. and Grasela, T.H. (1997) Symptomatic Cardiotoxicity Associated with 5-Fluorouracil. Pharmacotherapy, 17, 729-736.
[8]
Frishman, W.H., Sung, H.M., Yee, H.C., Liu, L.L., Einzig, A.I., Dutcher, J. and Keefe, D. (1996) Cardiovascular Toxicity with Cancer Chemotherapy. Current Problems in Cardiology, 21, 225-286. https://doi.org/10.1016/S0146-2806(96)80011-9
[9]
Taguchi, T. (1983) Effects of Lentinan in Advanced or Recurrent Cases of Gastric, Colorectal, and Breast Cancer. Japanese Journal of Cancer and Chemotherapy, 10, 387-393.
[10]
Nakagawa, M., Yamaguchi, T., Ueda, H., Shiraishi, N., Komiyama, S., Akiyama, S., Ogata, J. and Kuwano, M. (1985) Potentiation by Vitamin A of the Action of Anticancer Agents against Murine Tumors. Japanese Journal of Cancer Research, 76, 887-888.
[11]
Shoemaker, L. and Arora, U. (2004) Rocha Lima C. 5-Fluorouracil-Induced Coronary Vasospasm. Cancer Control, 11, 46-49. https://doi.org/10.1177/107327480401100107